WAYNE, Pa., March 31, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) (“Egalet”) today announced positive results of the first phase of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. The product uses Egalet’s proprietary technology which is specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API).
Help employers find you! Check out all the jobs and post your resume.
